Skip to main content

ADVERTISEMENT

Kimberly Vanover, PhD

Introduction: Lumateperone (lumateperone tosylate, ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that simultaneously modu...
11/22/2019
11/22/2019
Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...
11/22/2019